Takeda leaving no stone unturned in battle to overcome historical challenges of neuroscience
Takeda Pharmaceutical’s (TYO: 4502) vision in neuroscience is reminiscent of its approach in producing global vaccines, another massive healthcare challenge that the company has decided to confront head-on in recent years.
That approach is not to be put off by the high-profile failures that other companies have suffered in this space, with some big names exiting the area altogether because they believe the odds of finding an effective new drug in neurological conditions such as treatment-resistant depression or Alzheimer’s are just too low.
"The strategy to partnerships is to bring a maximum level of innovation into our portfolio, but also to bring together different kinds of minds and expertise that could be complimentary"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze